Q-omics provides the consensus-scored ANKRD12 profile across patient tissues and cancer cell-line models. ANKRD12 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, ANKRD12 is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, ANKRD12 RNA expression shows 21,574 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight SKCM, THCA, and THYM as cancer lineages where ANKRD12 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ANKRD12 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ANKRD12 survival associations across molecular data types. ANKRD12 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (6) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ANKRD12 RNA expression–survival associations across cancer types. High ANKRD12 expression shows unfavorable associations in UVM, but favorable associations in SKCM, KIRC, BRCA, GBM and HNSC. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for ANKRD12 RNA expression.
This table summarizes ANKRD12 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 3. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for ANKRD12. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ANKRD12 shows lower tumor expression in THCA, COAD, READ and UCEC and higher tumor expression in CHOL and LIHC. The THCA box plot shows higher ANKRD12 RNA expression in normal versus tumor tissue (log2 FC = −1.264, t-test p < 0.001).
This table shows molecular features associated with ANKRD12 in patient tissues and cancer cell lines. In patient samples, ANKRD12 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, ANKRD12 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Lymphoma.
